Myeloproliferative disease
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Myeloproliferative disease Classification and external resources | |
| ICD-10 | D47.1 |
|---|---|
| ICD-9 | 205.1, 238.4, 289.89, 289.9 |
| ICD-O: | 9950/0-9964/3 |
| MeSH | D009196 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The myeloproliferative diseases ("MPD"s) are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia, although the myeloproliferative diseases on the whole have a much better prognosis than these conditions. The concept of myeloproliferative disease was first proposed in 1951 by the eminent hematologist William Dameshek.[1]
Classification
Although not a malignant neoplasm, MPDs are classified within the hematological neoplasms.
There are four main myeloproliferative diseases, which can be further categorized by the presence of the Philadelphia chromosome:
| Philadelphia Chromosome "positive" | Philadelphia Chromosome "negative" |
|---|---|
|
Causes
All MPDs arise from precursors of the "myeloid" lineage in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).
Diagnosis
Depending on the nature of the myeloproliferative disorder, diagnostic tests may include red cell mass determination (for polycythaemia), bone marrow aspirate and trephine biopsy, arterial oxygen saturation and carboxyhaemoglobin level, neutrophil alkaline phosphatase level, vitamin B12 (or B12 binding capacity) and serum urate.<refLevene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders, 586. ISBN 0-443-06377-X. </ref>
In 2005, the discovery of the JAK2 V617F mutation provided some evidence to suggest a common pathogenesis for the Philadelphia Chromosome negative MPDs.[2][3][4][5][6]
References
- ↑ Dameshek W (1951). "Some speculations on the myeloproliferative syndromes.". Blood 6 (4): 372-5. PMID 14820991.
- ↑ Baxter EJ, Scott LM, Campbell PJ, et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.". Lancet 365: 1054-1061. PMID 15781101.
- ↑ James C, Ugo V, Le Couedic JP, et al. (2005). "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.". Nature 434 (7037): 1144–1148. PMID 15793561.
- ↑ Levine RL, Wadleigh M, Cools J, et al. (2005). "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis". Cancer Cell 7 (4): 387–397. PMID 15837627.
- ↑ Kralovics R, Passamonti F, Buser AS, et al. (2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N Engl J Med 352 (17): 1779–1790. PMID 15858187.
- ↑ Campbell PJ, Scott LM, Buck G, et al. (2005). "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study". Lancet 366 (9501): 1945–1953. PMID 16325696.
External links
- Myeloproliferative Disorders Website of The CMPD Education Foundation
- Myeloproliferative Disorders in practice
- Myeloproliferative Disease Support List
- MeSH Myeloproliferative+Disorders
- MPD Foundation and Research Alliance - Register for a free newsletter
Myeloid Hematological malignancy/leukemia histology (ICD-O 9590-9989, C81-C96, 200-208) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CFU-GM/ and other granulocytes |
| ||||||||||||||
| MEP |
| ||||||||||||||
| CFU-Mast | Mastocytoma (Mast cell leukemia, Mast cell sarcoma, Systemic mastocytosis) | ||||||||||||||
| Multiple/unknown | AML (Acute panmyelosis with myelofibrosis, Myeloid sarcoma) · MP (Myelofibrosis) · Acute biphenotypic leukaemia | ||||||||||||||
| See also hematology, lymphoid malignancy | |||||||||||||||
WikiDoc Research Resources for Myeloproliferative disease | |
|---|---|
| Articles on Myeloproliferative disease | Most recent articles on Myeloproliferative disease • Most cited articles on Myeloproliferative disease • Review articles on Myeloproliferative disease • Articles on Myeloproliferative disease in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Myeloproliferative disease | Powerpoint slides on Myeloproliferative disease • Images of Myeloproliferative disease • Photos of Myeloproliferative disease • Podcasts & MP3s on Myeloproliferative disease • Videos on Myeloproliferative disease |
| Evidence Based Medicine Regarding Myeloproliferative disease | Cochrane Collaboration on Myeloproliferative disease • Bandolier on Myeloproliferative disease • TRIP on Myeloproliferative disease |
| Cost Effectiveness of Myeloproliferative disease | Cost Effectiveness of Myeloproliferative disease |
| Clinical Trials Involving Myeloproliferative disease | Ongoing Trials on Myeloproliferative disease at Clinical Trials.gov • Trial results on Myeloproliferative disease • Clinical Trials on Myeloproliferative disease at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Myeloproliferative disease | US National Guidelines Clearinghouse on Myeloproliferative disease • NICE Guidance on Myeloproliferative disease • NHS PRODIGY Guidance • FDA on Myeloproliferative disease • CDC on Myeloproliferative disease |
| Textbook Information on Myeloproliferative disease | Books and Textbook Information on Myeloproliferative disease |
| Pharmacology Resources on Myeloproliferative disease | Dosing of Myeloproliferative disease • Drug interactions with Myeloproliferative disease • Side effects of Myeloproliferative disease • Allergic reactions to Myeloproliferative disease • Overdose information on Myeloproliferative disease • Carcinogenicity information on Myeloproliferative disease • Myeloproliferative disease in pregnancy • Pharmacokinetics of Myeloproliferative disease • |
| Genetics, Pharmacogenomics, and Proteinomics of Myeloproliferative disease | Genetics of Myeloproliferative disease • Pharmacogenomics of Myeloproliferative disease • Proteomics of Myeloproliferative disease |
| Newstories on Myeloproliferative disease | Myeloproliferative disease in the news • Be alerted to news on Myeloproliferative disease • News trends on Myeloproliferative disease |
| Commentary on Myeloproliferative disease | Blogs on Myeloproliferative disease |
| Patient Resources on Myeloproliferative disease | Patient resources on Myeloproliferative disease • Discussion groups on Myeloproliferative disease • Patient Handouts on Myeloproliferative disease • Directions to Hospitals Treating Myeloproliferative disease • Risk calculators and risk factors for Myeloproliferative disease |
| Healthcare Provider Resources on Myeloproliferative disease | Symptoms of Myeloproliferative disease • Causes & Risk Factors for Myeloproliferative disease • Diagnostic studies for Myeloproliferative disease • Treatment of Myeloproliferative disease |
| Continuing Medical Education (CME) Programs on Myeloproliferative disease | CME Programs on Myeloproliferative disease |
| International Resources on Myeloproliferative disease | Myeloproliferative disease en Espanol • Myeloproliferative disease en Francais |
| Business Resources on Myeloproliferative disease | Myeloproliferative disease in the Marketplace • Patents on Myeloproliferative disease |
| Informatics Resources on Myeloproliferative disease | List of terms related to Myeloproliferative disease |
de:Myeloproliferative Erkrankung
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
